
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx is a promising clinical-stage biopharmaceutical company that specializes in developing potent inhibitors of the complement activation factor, C5a, and its receptor, C5aR, for the treatment of various autoimmune and inflammatory diseases. The company recently announced positive financial results for the first quarter of 2026, with a significant increase in cash and marketable securities, which is expected to provide runway through 2029. In addition, InflaRx's product candidate, vilobelimab, has demonstrated promising disease-modifying clinical activity and tolerability in multiple clinical settings, making it a potential game-changer in the biotechnology industry.
Bears say
InflaRx is facing potential risks and challenges financially as they lack commercial assets and depend heavily on securing partnerships and funding in order to progress their pipeline. While their product candidate, izicopan, shows potential for autoimmune and inflammatory diseases, its efficacy and position in the market remains uncertain. Additionally, IFRX faces competition in the increasingly competitive CSU and HS market, and the success of their therapies heavily relies on positive clinical trial results and regulatory approvals.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares